Featured Research

from universities, journals, and other organizations

Insulin Drug Study Shows Significant Improvements In More Than 52,000 Diabetic Patients

Date:
March 9, 2009
Source:
Wiley - Blackwell
Summary:
Major diabetes study included 52,419 patients from Poland, Russia, Greece, Italy, Canada, China, India and Japan. 53% achieved blood glucose target of less than 7% set by International Diabetes Foundation. Average drop in blood glucose levels was 31%. Episodes of major hypoglycaemia fell by 94%. Patient satisfaction rose from 10% to 59%.

A major international diabetes study of more than 52,000 patients from eight countries has shown that using biphasic BIAsp 30 insulin resulted in significant clinical improvements and greater patient satisfaction.

Related Articles


The findings, reported in the March issue of the International Journal of Clinical Practice, show that 53 per cent achieved a blood glucose (HbA1c) level of less than seven per cent, the target set by the International Diabetes Foundation.

Based on the largest database of Type II Diabetes patients ever compiled, the first phase of the IMPROVE study covered eight countries: Canada, China, Greece, India, Italy, Japan, Poland and Russia.

Data for the Gulf region, Iran and South Korea will be available later this year.

The study looked at the safety and effectiveness of using the biphasic insulin, which contains both fast-acting and intermediate components, prescribed by family doctors and hospital consultants.

“Patients with Type II Diabetes who used the biphasic insulin saw their blood glucose levels drop by up to 31 per cent and episodes of major hypoglycaemia, where the glucose levels become very low, fell by an average of 94 per cent” explains Professor Paul Valensi, head of the Department of Endocrinology-Diabetology-Nutrition at the Jean Verdier Hospital in France, who led the research.

“They also expressed greater satisfaction in the treatment they received, with the percentage rising from 10 per cent at baseline to 59 per cent at the end of the study.”

A total of 52,419 patients were enrolled from three pre-study treatment groups:

  • 17 per cent were not receiving any antidiabetic treatment when they joined the study. Time since diagnosis averaged two years and HbA1c levels averaged 9.9 per cent.
  • 65 per cent were on oral antidiabetic drugs. Time since diagnosis averaged 7.4 years and HbA1c levels averaged 9.2 per cent.
  • 18 per cent were on injectable insulin, with or without oral antidiabetic drugs. Time since diagnosis averaged 10.4 years and HbA1c levels averaged 9.3 per cent.

“Patients are usually not started on insulin when they are diagnosed with Type II Diabetes” explains Professor Valensi. “Lifestyle changes and oral antidiabetic drugs are usually the first therapeutic steps, but some patients are unable to control their blood glucose levels using this method and insulin is the next step.”

Each patient took the biphasic insulin (marketed as NovoMix 30) as directed by their clinician for 26 weeks and data was recorded on each patient at baseline, three months and at the final visit. More than 95 per cent of the patients completed the study.

Reductions in blood glucose levels were significant in all three groups. Patients who had not previously received any diabetes treatment before they were included in the study achieved the biggest HbA1c reduction, down by an average of 31 per cent.

Patients who had only received oral medication before achieved an average fall of 23 per cent and patients who had received injectable insulin, with or without oral medication, achieved an average reduction of 22 per cent.

This took their average HbA1c levels down to 6.8 per cent, 7.1 per cent and 7.3 per cent respectively, with more than half of the patients achieving the seven per cent target set by the International Diabetes Foundation.

The study in IJCP contains detailed results for the 52,419 patients from the first eight countries to complete the study – Canada (1,594 patients), China (21,729), India (17,890), Japan (2,095), Poland (4,117), Russia (4,662), Greece (114) and Italy (218).

Patient demographics and clinical characteristics included:

  • Study participants had an average age of 55 and 57 per cent were male. They had an average body mass index of 26. Their average HbA1c (blood glucose level) was 9.3 per cent and average time since diagnosis was seven years.
  • Male patients were more likely to be receiving no pharmaceutical therapy at baseline than women (66 per cent versus 34 per cent), with 51 per cent of men and 49 per cent of women receiving insulin, with or without oral anti diabetic drugs.
  • Patients receiving no treatment had a lower average BMI (25) and average weight (69.7kg) than those who were on insulin, with or without oral antidiabetic drugs (BMI 27.5 and weight 73.6kg).

Just under a hundred patients (0.19 per cent) reported 110 serious adverse drug problems. The most common was major hypoglycaemia, where glucose levels become very low, with 69 patients reporting 81 incidents. Other less frequent reactions included drug hypersensitivity, injection site reaction and rash.

“Initiating insulin therapy with BIAsp 30, or switching patients from other medication to the drug, resulted in improved blood glucose control, fewer major incidents of major hypoglycaemia and improved patient satisfaction” concludes Professor Valensi.

“These statistically significant results were observed in the cohort as a whole, across the three subgroups and in the eight individual countries that have so far reported their detailed results.”


Story Source:

The above story is based on materials provided by Wiley - Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Valensi et al. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observationa. International Journal of Clinical Practice, 2009; 63 (3): 522 DOI: 10.1111/j.1742-1241.2009.02002.x

Cite This Page:

Wiley - Blackwell. "Insulin Drug Study Shows Significant Improvements In More Than 52,000 Diabetic Patients." ScienceDaily. ScienceDaily, 9 March 2009. <www.sciencedaily.com/releases/2009/03/090302090431.htm>.
Wiley - Blackwell. (2009, March 9). Insulin Drug Study Shows Significant Improvements In More Than 52,000 Diabetic Patients. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2009/03/090302090431.htm
Wiley - Blackwell. "Insulin Drug Study Shows Significant Improvements In More Than 52,000 Diabetic Patients." ScienceDaily. www.sciencedaily.com/releases/2009/03/090302090431.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Breakfast Debate: To Eat Or Not To Eat?

Breakfast Debate: To Eat Or Not To Eat?

Newsy (Oct. 23, 2014) Conflicting studies published in the same week re-ignited the debate over whether we should be eating breakfast. Video provided by Newsy
Powered by NewsLook.com
Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Despite Rising Death Toll, Many Survive Ebola

Despite Rising Death Toll, Many Survive Ebola

AP (Oct. 23, 2014) The family of a Dallas nurse infected with Ebola in the US says doctors can no longer detect the virus in her. Despite the mounting death toll in West Africa, there are survivors there too. (Oct. 23) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins